Our science

1/3

Technology platform

Unique 3D Tissue Regeneration Technology Platform

Platform is a 3-dimensional, scaffold-free, extracellular matrix with adipose-derived stem cells

Platform delivers growth factors and miRNAs to restore the physiology of natural healing

Novadip’s 3D technology platform drives multiple product classes

15 years of academic research combined with practical surgery experience

Initial clinical proof of concept data leveraged to optimize efficacy and safety

Novadip’s unique “3M3” platform for tissue regeneration combines over 15 years of academic research with practical surgery experience and proof of principle clinical data.

3M3

3-Dimensional, scaffold free

Matrix with ASCs to deliver growth factors/miRNA

Mature implant mimics physiology of natural healing

MiRNAs as bioactive agents

3 classes of product candidates

The 3M3 technology platform consists of a 3-dimensional, scaffold-free, extracellular matrix (ECM) utilizing differentiated adipose-derived stem cells (ASCs), to generate highly-specific growth factors and miRNAs to restore the physiology of natural healing

The technology is based on adipose-derived stem cells, which are easily harvested from fatty tissue and, when differentiated, have better osteogenic properties than bone marrow-derived stem cells.

The platform is based on a virtuous cycle that occurs between adipose-derived stem cells (ASCs) and that develops after adding active particles to the differentiated ASCs resulting in an ECM containing highly bioactive ASCs, with highly specific miRNAs, and high and stable amounts of growth factors and specific proteins, which together have properties necessary to promote tissue regeneration.

The technology is based on ASCs, which are easily harvested from fatty tissue and have better osteogenic properties than bone marrow-derived stem cells.

2/3

Manufacturing

Novadip has developed a robust manufacturing process and distribution platform for its autologous cell therapies. The manufacturing process and supply chain have the capability of rapidly delivering the product candidates globally.

Manufacturing process is in GMP-certified facility

– Low starting material variability and no rejection of any manufactured batch
– Extensive in-house characterization and quailty control testing
– Process ready for optimization and scale-out
– Own manufacturing plant with capacity >70 patients/year

Starting Material

Few cc/mL of adipose tissue

No animal-derived materials

Expansion

Few number of passages

Small scale process

Differentiation, 3D induction

Large volume (>20cc)

Drug substance stable for several weeks

Final Product

Stable at room temp for several days

3/3

Publications

Allogenic 3D scaffold-free tissue engineered product for deep thickness skin...

December 18, 2019

A scaffold-free graft for large critical size bone defect: preclinical...

December 18, 2019

The in vivo immunogenicity of a human 3D scaffold-free tissue...

December 18, 2019

Monitoring of cell culture conditions and early prediction of the...

December 18, 2019

Genetic stability assessment in bone tissue-engineered products

December 18, 2019